TABLE 3

Results of base-case analysis

Usual careIvacaftor plus usual careIncremental value#
Receiving lung transplantation %30.27 (27.26–34.31)12.00 (8.87–16.18)−18.27 (−22.85– −13.63)
Estimated life expectancy years47.78 (46.66–49.21)66.04 (61.35–70.11)18.25 (13.71–22.20)
Estimated quality-adjusted life-years42.15 (41.15–43.37)57.18 (53.02–61.19)15.03 (11.13–18.73)
Estimated lifetime cost US$1 130 184 (461 764–3 435 325)4 504 768 (3 442 654–5 892 376)3 374 584 (1 651 192–4 634 390)
  • Data are presented as n (95% credible interval). All findings estimated based on the 25-year-old starting cohort. #: ivacaftor plus usual care versus usual care alone.